Loading market dashboard
Nxera Pharma Co., Ltd.
SOLTFHealthcareOTCJP
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Tokyo, Japan and Cambridge, UK, 2 June 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.
Tokyo, Japan and Cambridge, UK, 26 May 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference on Wednesday,3rd June at 3:45 p.m. EDT / 4th 4:45 a.m. JST. During the event, Mr. Cargill will present the Company's strategy, recent progress and expected upcoming milestones to leading global life sciences investors.
Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) entered into a license agreement with a newly established company (“NewCo”) to advance a specific GPCR-targeted program owned by Nxera. Nxera today announces that, in connection with the closing of a Series A financing undertaken by NewCo, Nxera and a syndicate of leading healthcare and life sciences-focused investors have entered into an investment agreement with NewCo. NewCo will accelerate preclinical studies of a GPCR program against a target discovered using Nxera's NxWave™ technology platform and advance the program toward global clinical trials. By participating in the Series A financing, Nxera will continue its partnership with NewCo to maximize impact for patients and the value of the program for shareholders.
Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has issued proceedings against OMass Therapeutics alleging infringement of its patents EP 3 408 286 B1 and GB 2 558 968 B relating to its proprietary miniG technology. miniG is an integral part of Nxera's NxWave™ GPCR-focused structure-based drug discovery platform.
Tokyo, Japan and Cambridge and London, UK, 20 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a third R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.
Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF - Get Free Report) saw a significant decline in short interest in March. As of March 31st, there was short interest totaling 1,523,938 shares, a decline of 13.8% from the March 15th total of 1,768,441 shares. Based on an average daily volume of 275 shares, the days-to-cover ratio is currently
Tokyo, Japan and Cambridge, UK, 14 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Holling Bio-Pharma Corp. (“Holling”), a leading pharmaceutical distribution and commercialization company based in Taipei, Taiwan, has received approval from the Taiwan Food and Drug Administration (“TFDA”) to market and sell QUVIVIQ® (daridorexant, marketed in Taiwan under the product name 科唯可® film-coated tablets) 25 and 50 mg for the treatment of adults with insomnia. Plans are underway to launch QUVIVIQ® in Taiwan during 2026.
Tokyo, Japan and Cambridge, UK, 13 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated and dosed the first patient(s) in a Phase 2 clinical study of NBI-1117570 (“NBI-'570”) in adults with schizophrenia. As a result, Nxera will receive milestone payments of US$22.5 million from Neurocrine pursuant to the agreement. The milestone payments will be recognised as revenue in Q1 FY2026. NBI-‘570 is an investigational, orally administered, dual muscarinic M1/M4 receptor agonist discovered using Nxera's proprietary NxWave™ drug discovery platform.
Tokyo, Japan and Cambridge, UK, 09 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requirements as the achievement of the milestone represents significant progress in research and development for Nxera.
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa's OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a material economic interest in its future development and commercialization Tokyo, Japan and Cambridge, UK, 1 April 2026 - Nxera Pharma Co.
